RNA, Viral; Adaptive Immunity/physiology; Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Coinfection/blood; Coinfection/epidemiology; Coronavirus/genetics; Coronavirus/immunology; Coronavirus Infections/blood; Coronavirus Infections/epidemiology; Coronavirus Infections/immunology; Coronavirus Infections/virology; Follow-Up Studies; HIV Infections/complications; HIV Infections/epidemiology; Humans; Male; Middle Aged; Netherlands/epidemiology; Pandemics; RNA, Viral/analysis; RNA, Viral/blood; Reinfection/blood; Reinfection/epidemiology; Reinfection/immunology; Reinfection/virology; SARS-CoV-2/genetics; SARS-CoV-2/immunology; Serologic Tests/methods; Time Factors; Young Adult; COVID-19/blood; COVID-19/epidemiology; COVID-19/immunology; COVID-19/prevention & control; Seasons; Adaptive Immunity; Coinfection; Coronavirus; Coronavirus Infections; COVID-19; HIV Infections; Netherlands; Reinfection; SARS-CoV-2; Serologic Tests; Biochemistry, Genetics and Molecular Biology (all); General Biochemistry, Genetics and Molecular Biology; General Medicine
Abstract :
[en] A key unsolved question in the current coronavirus disease 2019 (COVID-19) pandemic is the duration of acquired immunity. Insights from infections with the four seasonal human coronaviruses might reveal common characteristics applicable to all human coronaviruses. We monitored healthy individuals for more than 35 years and determined that reinfection with the same seasonal coronavirus occurred frequently at 12 months after infection.
Disciplines :
Immunology & infectious disease
Author, co-author :
Edridge, Arthur W D ; Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
Kaczorowska, Joanna; Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
Hoste, Alexis ; Université de Liège - ULiège > Département GxABT > Microbial technologies ; INGENASA, Inmunología y Genética Aplicada S. A., Madrid, Spain
Bakker, Margreet; Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
Klein, Michelle ; Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
Loens, Katherine; Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium ; Department of Microbiology, University Hospital Antwerp, Edegem, Belgium
Jebbink, Maarten F; Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
Matser, Amy; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
Kinsella, Cormac M ; Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
Rueda, Paloma; INGENASA, Inmunología y Genética Aplicada S. A., Madrid, Spain
Ieven, Margareta; Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium
Goossens, Herman; Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium ; Department of Microbiology, University Hospital Antwerp, Edegem, Belgium
Prins, Maria; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands ; Amsterdam UMC, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
Sastre, Patricia; INGENASA, Inmunología y Genética Aplicada S. A., Madrid, Spain
Deijs, Martin; Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
van der Hoek, Lia ; Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. c.m.vanderhoek@amsterdamumc.nl
The authors gratefully acknowledge the Amsterdam Cohort Studies (ACS) on HIV infection and AIDS, a collaboration among the Public Health Service of Amsterdam, the Amsterdam University Medical Center of the University of Amsterdam, the Sanquin Blood Supply Foundation, the Medical Center Jan van Goyen and the HIV Focus Center of the DC-Clinics. It is part of the Netherlands HIV Monitoring Foundation and financially supported by the Center for Infectious Disease Control of the Netherlands National Institute for Public Health and the Environment. The authors thank all ACS participants for their contribution, as well as the ACS study nurses, data managers and lab technicians. We thank K. Jacobs for his help with lifting of GRACE consortium samples and D. Eggink for PREPARE consortium samples. We acknowledge the GRACE network (LSHM-CT-2005–518226), the European Science Foundation Research Networking Programmes network TRACE and the PREPARE project (funded through the European Union FP7 Programme no. 602525). This work was supported by a grant from the European Union’s Horizon 2020 Research and Innovation Programme, under Marie Skłodowska-Curie Actions grant agreement no. 721367 (HONOURs), Amsterdam University Medical Center funding connected to HONOURs and the Amsterdam University Medical Center PhD scholarship of A. W. D. Edridge.
Pyrc, K. et al. Mosaic structure of human coronavirus NL63, one thousand years of evolution. J. Mol. Biol. 364, 964–973 (2006). DOI: 10.1016/j.jmb.2006.09.074
Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. J. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105, 435–446 (1990). DOI: 10.1017/S0950268800048019
Van Bilsen, W. P. H. et al. Diverging trends in incidence of HIV versus other sexually transmitted infections in HIV-negative MSM in Amsterdam. AIDS 34, 301–309 (2020). DOI: 10.1097/QAD.0000000000002417
Blanchard, E. G., Miao, C., Haupt, T. E., Anderson, L. J. & Haynes, L. M. Development of a recombinant truncated nucleocapsid protein based immunoassay for detection of antibodies against human coronavirus OC43. J. Virol. Methods 177, 100–106 (2011). DOI: 10.1016/j.jviromet.2011.07.005
Li, Y., Wang, X. & Nair, H. Global seasonality of human seasonal coronaviruses: a clue for postpandemic circulating season of severe acute respiratory syndrome coronavirus 2? J. Infect. Dis. 222, 1090–1097 (2020).
Reed, S. E. The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: evidence of heterogeneity among 229E‐related strains. J. Med. Virol. 13, 179–192 (1984). DOI: 10.1002/jmv.1890130208
Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200–1204 (2020). DOI: 10.1038/s41591-020-0965-6
Ibarrondo, F. J. et al. Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild Covid-19. N. Engl. J. Med. 10.1056/NEJMc2025179 (2020).
Ieven, M. et al. Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries. Clin. Microbiol. Infect. 24, 1158–1163 (2018). DOI: 10.1016/j.cmi.2018.02.004
Gobat, N. et al. Preparedness for clinical research during pandemics: a perspective from the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE). Lancet 392, S38 (2018).
Loens, K. et al. Performance of different mono- and multiplex nucleic acid amplification tests on a multipathogen external quality assessment panel. J. Clin. Microbiol. 50, 977–987 (2012). DOI: 10.1128/JCM.00200-11
Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493–497 (1938). DOI: 10.1093/oxfordjournals.aje.a118408
Dijkman, R. et al. The dominance of human coronavirus OC43 and NL63 infections in infants. J. Clin. Virol. 53, 135–139 (2012). DOI: 10.1016/j.jcv.2011.11.011
Severance, E. G. et al. Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population. Clin. Vaccin. Immunol. 15, 1805–1810 (2008). DOI: 10.1128/CVI.00124-08
Sastre, P. et al. Differentiation between human coronaviruses NL63 and 229E using a novel double-antibody sandwich enzyme-linked immunosorbent assay based on specific monoclonal antibodies. Clin. Vaccin. Immunol. 18, 113–118 (2011). DOI: 10.1128/CVI.00355-10
Dijkman, R. et al. Human coronavirus NL63 and 229E seroconversion in children. J. Clin. Microbiol. 46, 2368–2373 (2008). DOI: 10.1128/JCM.00533-08
Lehmann, C. et al. A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses. Diagn. Microbiol. Infect. Dis. 61, 40–48 (2008). DOI: 10.1016/j.diagmicrobio.2007.12.002
Gorse, G. J., Donovan, M. M. & Patel, G. B. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus‐associated illnesses. J. Med. Virol. 92, 512–517 (2020). DOI: 10.1002/jmv.25715
van der Hoek, L. et al. Identification of a new human coronavirus. Nat. Med. 10, 368–373 (2004). DOI: 10.1038/nm1024
